How have ALZN shares performed in 2024?

Alzamend Neuro's stock was trading at $0.89 at the beginning of the year. Since then, ALZN stock has decreased by 24.1% and is now trading at $0.6755. View the best growth stocks for 2024 here .

Are investors shorting Alzamend Neuro?

Alzamend Neuro saw a decline in short interest in March. As of March 31st, there was short interest totaling 45,300 shares, a decline of 11.5% from the March 15th total of 51,200 shares. Based on an average daily volume of 54,600 shares, the short-interest ratio is currently 0.8 days. Currently, 0.9% of the shares of the company are sold short. View Alzamend Neuro's Short Interest .

When is Alzamend Neuro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our ALZN earnings forecast .

How were Alzamend Neuro's earnings last quarter?

Alzamend Neuro, Inc. (NASDAQ:ALZN) released its earnings results on Monday, March, 25th. The company reported ($0.38) EPS for the quarter.

When did Alzamend Neuro's stock split?

Alzamend Neuro's stock reverse split on the morning of Tuesday, October 31st 2023. The 1-15 reverse split was announced on Tuesday, October 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Alzamend Neuro IPO?

Alzamend Neuro (ALZN) raised $12 million in an IPO on Tuesday, June 15th 2021. The company issued 2,500,000 shares at a price of $5.00 per share. Spartan Capital Securities, LLC served as the underwriter for the IPO and -- was co-manager.

How do I buy shares of Alzamend Neuro?

Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALZN

Alzamend Neuro (ALZN) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ALZN Stock Alerts

$0.68

-0.02 (-2.88%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.65
▼
$0.71
50-Day Range: $0.69
▼
$1.20
52-Week Range: $0.65
▼
$11.91

Volume: 27,986 shs
Average Volume: 53,461 shs
Market Capitalization: $4.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Alzamend Neuro alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Alzamend Neuro Stock (NASDAQ:ALZN)

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

ALZN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALZN Stock News Headlines

April 17, 2024 | msn.com

Alzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42

March 26, 2024 | msn.com

ALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

February 24, 2024 | msn.com

Alzamend Neuro (ALZN) Price Target Increased by 25.00% to 25.50

February 13, 2024 | realmoney.thestreet.com

Maxim gets more bearish on Alzamend Neuro, downgrades shares

February 3, 2024 | msn.com

Alzamend Neuro Risks Nasdaq Delisting Over Price Deficiency

December 19, 2023 | markets.businessinsider.com

Buy Rating for Alzamend Neuro Amid Promising Alzheimer’s Drug Trials and Market Potential

December 18, 2023 | msn.com

ALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

December 18, 2023 | msn.com

ALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024

December 11, 2023 | finance.yahoo.com

Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients

December 11, 2023 | finance.yahoo.com

EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year

November 20, 2023 | marketwatch.com

Alzamend Neuro Gets FDA Approval for Trial of Depression Treatment

November 20, 2023 | msn.com

EXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder Study

November 20, 2023 | finance.yahoo.com

Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

November 16, 2023 | finance.yahoo.com

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

November 13, 2023 | msn.com

EXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug Candidate

November 13, 2023 | finance.yahoo.com

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001

November 2, 2023 | msn.com

Alzamend Neuro (ALZN) Price Target Increased by 1306.25% to 57.38

October 30, 2023 | benzinga.com

Why Alzamend Neuro (ALZN) Stock Is Nosediving Today

October 30, 2023 | finance.yahoo.com

Alzamend Neuro Announces Reverse Stock Split

October 25, 2023 | finance.yahoo.com

Alzamend Neuro, Inc. (9ZT0.F)

October 23, 2023 | businesswire.com

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001

October 2, 2023 | msn.com

EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder

October 2, 2023 | finance.yahoo.com

Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

September 27, 2023 | seekingalpha.com

Alzamend Neuro CFO Katzoff buys 53K shares

September 26, 2023 | yahoo.com

Rep. Jennifer Wexton Will Not Run for Re-Election After Rare Neurological Disorder Diagnosis

See More Headlines

Receive ALZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/25/2024
Today: 4/19/2024
Fiscal Year End: 4/30/2024
Next Earnings (Estimated): 7/25/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ALZN
CUSIP: N/A
CIK: 1677077
Web: www.alzamend.com
Phone: 844-722-6303
Fax: N/A
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.9895)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,880,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -612.26%
Return on Assets: -255.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.16
Quick Ratio: 0.16

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.47 per share
Price / Book: 1.47

Miscellaneous

Outstanding Shares: 6,870,000
Free Float: 6,121,000
Market Cap: $4.75 million
Optionable: Optionable
Beta: 0.02

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Stephan Jackman (Age 47)
CEO & Director
Comp: $434.24k
Mr. David J. Katzoff (Age 61)
Chief Financial Officer
Comp: $116.67k
Mr. Milton Charles Ault III (Age 54)
Founder & Vice Chairman

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALZN Stock Analysis - Frequently Asked Questions

How have ALZN shares performed in 2024?: Alzamend Neuro's stock was trading at $0.89 at the beginning of the year. Since then, ALZN stock has decreased by 24.1% and is now trading at $0.6755.
View the best growth stocks for 2024 here.
Are investors shorting Alzamend Neuro?: Alzamend Neuro saw a decline in short interest in March. As of March 31st, there was short interest totaling 45,300 shares, a decline of 11.5% from the March 15th total of 51,200 shares. Based on an average daily volume of 54,600 shares, the short-interest ratio is currently 0.8 days. Currently, 0.9% of the shares of the company are sold short.
View Alzamend Neuro's Short Interest.
When is Alzamend Neuro's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our ALZN earnings forecast.
How were Alzamend Neuro's earnings last quarter?: Alzamend Neuro, Inc. (NASDAQ:ALZN) released its earnings results on Monday, March, 25th. The company reported ($0.38) EPS for the quarter.

When did Alzamend Neuro's stock split?: Alzamend Neuro's stock reverse split on the morning of Tuesday, October 31st 2023. The 1-15 reverse split was announced on Tuesday, October 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
When did Alzamend Neuro IPO?: Alzamend Neuro (ALZN) raised $12 million in an IPO on Tuesday, June 15th 2021. The company issued 2,500,000 shares at a price of $5.00 per share. Spartan Capital Securities, LLC served as the underwriter for the IPO and -- was co-manager.
How do I buy shares of Alzamend Neuro?: Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALZN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial